Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Award of the Dr A.T. Shousha Foundation Prize and Fellowship To Dr. Walid Ammar



Regional Committee for the Eastern Mediterranean                                                                    EM/RC63/INF.DOC.7 Rev.1
Sixty-third session                                                                                                                                           September 2016 
Provisional agenda item 9(a)


Award of the Dr A.T. Shousha Foundation Prize and Fellowship
 
  1. Following the recommendations of the Dr A.T. Shousha Foundation Committee at the Sixty-second Session of the World Health Organization (WHO) Regional Committee for the Eastern Mediterranean, the Executive Board awarded the Dr A.T. Shousha Foundation Prize for 2016, by decision EB138(5), to Dr Walid Ammar (Lebanon) for his significant contribution to public health in the geographical area in which Dr Shousha served WHO.
 
  1. Dr Walid Ammar is being honoured for his significant contribution to public health in Lebanon, in particular in the areas of primary health care and health policy, and for his efforts in translating research and evidence into policy, programmes and practice and his efforts to voice the interests of the Region in all WHO forums. Dr Ammar graduated from the medical college of the Université Libre de Bruxelles, Belgium, in 1982, and received a master’s degree in public health and a diplôme d’études approfondies from the Lebanese University in 1996. In 2001, he was awarded a PhD in epidemiology from the Université Victor Segalen in Bordeaux, France (Université Bordeaux II).
 
  1. Since 1993, Dr Ammar has been Director-General of the Ministry of Public Health of Lebanon, bringing together a range of stakeholders to chart a vision for the welfare, rights and health care in an open network model of governance. Among other achievements, Dr Ammar set up Lebanon’s primary health care network in 1994 and initiated the first national hospital accreditation system in the Eastern Mediterranean Region, and was instrumental in strengthening and developing the Lebanese health care system. In a time of political instability and under his leadership, reforms led to significant improvement in health indicators while decreasing the GDP share of health expenditures, mostly as a result of meaningful reduction in household out-of-pocket spending.
 
  1. Dr Ammar is a model for public health professionals, having served not only in government and in the academic community but also in numerous national, regional and international organizations, boards and councils. Dr Ammar has produced numerous publications in the areas of health systems, health reform and good governance. His work as a researcher has led to the development of major studies which have been pivotal in reforming the health care system of Lebanon. 
Attribution du Prix et de la Bourse d’études de la Fondation Dr A.T. Shousha a Dr. Walid Ammar
 
Awarding Ceremony, Cairo, October 3, 2016-Laureat address-Walid Ammar MD, Ph.D



    2
    ...
ATC Name B/G Ingredients Dosage Form Price
A10BD15 XIGDUO XR B Metformin HCl XR - 1000mg, Dapagliflozin - 10mg Tablet 3,006,579 L.L
B01AC27 UPTRAVI B Selexipag - 200mcg 200mcg Tablet, film coated 242,569,645 L.L
C08DA01 ISOPTIN B Verapamil (HCl) - 80mg 80mg Tablet, film coated 397,704 L.L
H03BB02 THYROZOL B Methimazole (Thiamazole) - 10mg 10mg Tablet, film coated 326,554 L.L
J01DD15 OMNICEF B Cefdinir - 250mg/5ml 250mg/5ml Powder for suspension 3,670,034 L.L
R07AA INFASURF B Calfactant - 210mg/6ml 35mg/ml Injectable suspension 40,596,749 L.L
H01CB02 SANDOSTATIN LAR B Octreotide (acetate) - 30mg 30mg Injectable powder for suspension+diluent L.L
B01AC27 UPTRAVI B Selexipag - 200mcg 200mcg Tablet, film coated 552,391,145 L.L
C08DA01 ISOPTIN SR B Verapamil (HCl) - 240mg 240mg Tablet, film coated, prolonged release 1,128,821 L.L
C09DX03 VOCADO HCT B Olmesartan medoxomil - 40mg, Amlodipine - 5mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 1,523,917 L.L
J01DD52 ZAVICEFTA B Ceftazidime - 2g, Avibactam - 0.5g Injectable powder for concentrate for solution 101,659,975 L.L
J02AC03 VFEND B Voriconazole - 200mg 200mg Tablet, film coated 51,904,550 L.L
M02AA10 FASTUM B Ketoprofen - 2.5g/100g 2.5% Gel 177,387 L.L
R07AA INFASURF B Calfactant - 105mg/3ml 35mg/ml Injectable suspension 23,344,161 L.L
A06AB02 DULCOLAX B Bisacodyl - 5mg 5mg Tablet, sugar coated 520,067 L.L
B01AC27 UPTRAVI B Selexipag - 400mcg 400mcg Tablet, film coated 242,569,645 L.L
C08DA51 TARKA B Verapamil - 180mg, Trandolapril - 2mg Capsule, modified release 2,422,948 L.L
L01BC07 VIDAZA B Azacitidine - 100mg 100mg Injectable lyophilised powder 15,158,791 L.L
M02AA10 FASTUM B Ketoprofen - 2.5g/100g 2.5% Gel 337,304 L.L
R03AK08 INUVER B Formoterol fumarate - 6mcg/dose, Beclometasone dipropionate - 100mcg/dose Inhalation solution 3,225,222 L.L
R07AA01 SURVANTA B Colfosceril palmitate - 200mg/8ml 200mg/8ml Suspension 36,957,499 L.L
A02AC10 RENNIE B Magnesium carbonate - 80mg, Calcium carbonate - 680mg Tablet, chewable 240,548 L.L
A06AB02 DULCOLAX B Bisacodyl - 5mg 5mg Tablet, sugar coated 219,046 L.L
B01AC27 UPTRAVI B Selexipag - 600mcg 600mcg Tablet, film coated 242,569,645 L.L
C08DA51 TARKA B Verapamil - 240mg, Trandolapril - 4mg Tablet, modified release 3,797,532 L.L
C09DX04 ENTRESTO B Valsartan - 26mg, Sacubitril - 24mg Tablet, film coated 6,029,821 L.L
G03DA04 CRINONE B Progesterone - 8% 8% Gel 4,734,357 L.L
R03AK08 INUVER NEXTHALER B Formoterol fumarate dihydrate - 6mcg/dose, Beclometasone dipropionate - 100mcg/dose Inhalation powder 4,031,528 L.L
L02BA03 FASLODEX B Fulvestrant - 250mg/5ml 250mg/5ml Injectable solution L.L
A02AC10 TUMS EXTRA STRENGTH 750 ASSORTED FRUIT B Calcium carbonate - 750mg Tablet, chewable 421,967 L.L
    2
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026